Aligning Clinical Trial Findings With Real-World Ocular Toxicity Outcomes with ADCs in Solid Tumors

In this segment, the expert faculty reflects on how ocular toxicities observed in clinical practice align with outcomes reported in ADC clinical trials across gynecologic, breast, and lung oncology. The panel notes a strong overall consistency between trial data and real-world experience. They report that most gynecologic oncology patients experience grade 1–2 ocular adverse events, with symptoms typically manageable through adherence to mitigation strategies such as preservative-free lubricating drops. Required baseline and interval eye exams further help identify issues early. Dose reductions have been rare in his practice.

Expert faculty shares similar findings in breast cancer, noting that ocular events with datopotamab deruxtecan (Dato-DXD) are generally mild and rarely require treatment modification; stomatitis has been more clinically challenging than eye toxicity.

In the lung cancer setting, the faculty similarly reports that ocular effects with Dato-DXD are manageable with consistent use of eye drops, and dose reductions for eye-related reasons have been unnecessary.